Method for producing pure human-derived monoclonal antibody by mixed cell culture

Abstract

The invention relates to a method for producing a pure human-derived monoclonal antibody by mixed cell culture, which comprises the following steps: co-culturing T-cells, B-cells and human lymph node endothelial cells, and activating specific immunological cells with antigen to promote B-cell division and proliferation, thereby obtaining a monoclonal antibody cell strain with antigenic specificity; and obtaining the pure human-derived monoclonal antibody. The technique adopted by the invention is a mixed cell culture method, is simple and easy to implement and convenient to operate, settles a matter at one go, has a simple screening process, and saves substantial human and material resources; by using the invention, the production efficiency of the monoclonal antibody is greatly enhanced, and the yield of producing antibody from fusion cells is multiplied; and most cloning successfully implements the transformation from Type IgM to IgG, so that the production probability of the IgG type monoclonal antibody is greatly increased.

Description

technical field [0001] The invention belongs to the field of immunoglobulin preparation, and in particular relates to a method for producing pure human monoclonal antibodies by mixed cell culture. In the method, T cells, B cells, and human lymph node endothelial cells are co-cultured, and specific immune cells are subjected to Antigen activation promotes the division and proliferation of B cells, thereby obtaining antigen-specific monoclonal antibody cell lines, and then obtaining pure human monoclonal antibodies. Background technique [0002] Monoclonal antibody pharmacy is currently the fastest growing field of biotechnology in biopharmaceuticals. At present, the R&D and production of monoclonal antibody drugs can be roughly divided into three categories: 1) direct immunization of animals (including humanized mice); 2) gene library screening, including phage library and yeast expression library, etc.; 3) other biological learning method. However, these methods are diffic...

AI Technical Summary

Problems solved by technology

However, the introduction of EBV virus is a high-risk process of biological contamination, and the harm it produces is far greater than its positive effect; it can only be explored in scientific experiments, and it is impossible to apply it to biopharmaceuticals

Generally speaking, the success rate of this type of test is very low, and it is hardly operable

Images